Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes

• DOI: 10.1038/s41467-020-15913-6
• Publication Date: 2020-04-24T10:27:15Z
• Authors: Deli Liu; Jonathan E. Shoag; Daniel Poliak; Ramy S. Goueli; Vaishali Ravikumar; David Redmond; Aram Vosoughi; Jacqueline Fontugne; Heng Pan; Daniel Lee; Domonique Thomas; Keyan Salari; Zongwei Wang; Alessandro Romanel; Alexis Te; Richard Lee; Bilal Chughtai; Aria F. Olumi; Juan Miguel Mosquera; Francesca Demichelis; Olivier Elemento; Mark A. Rubin; Andrea Sboner; Christopher E. Ba...
• Keywords: Profiling (computer programming)

Benign prostatic hyperplasia (BPH), a nonmalignant enlargement of the prostate, is among most common diseases affecting aging men, but underlying molecular features remain poorly understood, and therapeutic options are limited. Here we employ comprehensive investigation BPH, including genomic, transcriptomic epigenetic profiling. We find no evidence neoplastic in BPH: driver genomic alterations, low coding mutation rates, mutational signatures consistent with tissues, minimal copy number rearrangements. At level, global hypermethylation dominant process. Integrating transcriptional methylation identifies two BPH subgroups distinct clinical signaling pathways, validated independent cohorts. Finally, mTOR inhibitors emerge as potential subtype-specific option, men exposed to show significant decrease prostate size. conclude that consists subgroups, for precision therapy.